Skip to main content
. 2022 Aug 10;187(6):866–877. doi: 10.1111/bjd.21743

Figure 4.

Figure 4

Time to first loss of ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) response through week 52. Maintenance period, rerandomized maintenance intention‐to‐treat population (OASIS‐1). The time of last dose prior to randomization is week 12. CI, confidence interval; HR, hazard ratio; MIRI, mirikizumab; NA, not applicable; Q8W, every 8 weeks. The numbers of patients at risk in brackets represent the number, of those being assessed, who lost or did not maintain PASI 90. aHR stratified by bodyweight (< 100 kg or ≥ 100 kg). b P‐value (two sided): log‐rank test for comparison with placebo Q8W stratified by bodyweight (< 100 kg or ≥ 100 kg).